Belgium Data Desk › Health › Health outcomes and resource use by patients treated with Besponsa for relapsed/refractory B-cell acute lymphoblastic leukemiea
Health outcomes and resource use by patients treated with Besponsa for relapsed/refractory B-cell acute lymphoblastic leukemiea
Besponsa (inotuzumab ozogamicin) is a medicine indicated in the treatment of relapsed or refractory CD22-positive precursor-B-cel acute lymphoblastic leukemia. It will be reimbursed and there will be a different reimbursement § for each treatment cycle. The prescribing physician only needs to complete the CIVARS reques
- Publisher
- Pfizer
- Licence
- ODC-BY
Open licence — reuse allowed, usually with attribution - Topic
- Health
- Type
- Dataset
- Last updated (catalogue)
- 2026-08-11
- Formats
- CSV, JSON, HTML
- Contact
- medical.information@pfizer.com
Open in Belgium Data DeskPreview, profile and run SQL in your browser
Official page at the publisher ↗
Download link checked on 2026-10-04: 3 of 3 worked. This page describes catalogue information. It does not state that the data is correct.
More in this topic
- ATMO-Street annual high-resolution model outputsBelgian Interregional Environment Agency · No licence stated in the catalogue
- NomenSoft coordinated reference tablesRIZIV / INAMI · No licence stated in the catalogue
- NomenSoft update filesRIZIV / INAMI · No licence stated in the catalogue
- PM10 rolling 24h mean — station featuresBelgian Interregional Environment Agency · No licence stated in the catalogue
- RIO annual/daily results by communeBelgian Interregional Environment Agency · No licence stated in the catalogue